The anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.
Related to this article
Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
Alembic's generic venetoclax, therapeutically equivalent to Venclexta, received final FDA approval for CLL/SLL and newly diagnosed AML.
Advertisement
Advertisement
Trending on OncLive
1
Governor Hochul Announces Historic Cancer Care Training Partnership Between New York and Puerto Rico Medical Institutions at SOMOS Conference 2026
2
Interpreting HER2 Results on Reports and Why the Tyrosine Kinase Domain Matters
3
Classification and Grading of Neuroendocrine Tumors
4
Retesting Strategies and PSMA PET Selection in Advanced Prostate Cancer
5